FibroGen regains rights to anemia drug from AstraZeneca (updated)

Kyntra Bio

26/02/2024 21:34

(Adds details in paragraphs 2 to 4)
       Feb 26 (Reuters) - FibroGen Inc  FGEN.O  said on Monday
it is regaining rights to the anemia drug, roxadustat, from
AstraZeneca  AZN.L  in the United States and certain other
territories after the companies agreed to terminate their over a
decade-long collaboration deal.
    The companies, however, continue to collaborate on the
development and commercialization of roxadustat in China.
    Under the deal, AstraZeneca held development and
commercialization rights in the US and other territories outside
of China not licensed to Astellas Pharma Inc  4503.T .
    FibroGen said it is exploring other licensing opportunities
for roxadustat.  

 (Reporting by Sriparna Roy in Bengaluru; Editing by Shailesh
Kuber)
 ((Sriparna.Roy@thomsonreuters.com;))